Presentation

Cutiss is a Swiss clinical-stage life sciences company focused on regenerative medicine and skin tissue engineering. It is developing the first personalised and automated skin tissue therapy for patients with severe skin injuries. The lead product denovoSkin is a bio-engineered and personalised dermo-epidermal human skin graft, currently in Ph2b clinical trials in Switzerland and the EU, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA. Cutiss is also developing the world’s first machine that can automate the entire production process of the personalised skin graft.

Recent highlights
In January, Cutiss announced the opening of its wholly owned R&D subsidiary based at EU’s leading technology park Sophia Antipolis and securing its first grant of EUR 300,000 from the Provence-Alpes-Côte d’Azur region that will be used to set up and launch the research laboratory. In February, Cutiss announced an exclusive licensing agreement with IBSA Pharma that grants Cutiss an exclusive worldwide license to commercialise VitiCell® developed by IBSA for the treatment of skin pigmentation disorders. In March, Cutiss announced the start of production at the company’s new onsite manufacturing facility, which is located at the company’s headquarters and covers a surface area of 150 sqm and is comprised of several laboratories including a biobank and a histology lab.

Outlook
The company aims to complete its Ph2b denovoSkin™ trial in Europe and Switzerland by 2022. The company is also working on the scale-up of the production process by means of automation.